influenza virus ia major caps respiratory ill given disease sever assoc economy cost recent appear novel strain renew interest develop efficacy universe vaccine strategy studi highlight immune capable genre local ie nasal mucosa lung tissueresid memory b cell admit system immune offer greatest protect future count current vaccine design lang stimuli iavspecif antibody genre lungresid induce infect herein report entrants admins biocompat polyanhydrid nanoparticles vaccine iavnanovax provide subset homolog heterolog nbr outer popup find also demons promote induce german center within lung cd altogether show nanovaccin induce similar occur thu could prove use strategy 